本研究旨在探讨胰腺导管腺癌切除患者辅助S-1化疗的相对剂量强度（RDI）与腰大肌质量体积（PMV）之间的预后关系。我们招募了 105 名经组织学证实为胰腺导管腺癌且接受了胰腺切除术的患者。 105 名患者中的 72 名 (68.6%) 接受了辅助 S-1 化疗，其余 33 名患者则没有接受辅助 S-1 化疗。接受辅助 S-1 化疗的患者根据 RDI 截止值分为高 RDI 组和低 RDI 组。高 RDI 组的五年总生存率 (OS) 和无复发生存率 (RFS) 显着高于低 RDI 组。同样，高 PMV 组患者的 5 年 OS 和 RFS 率均显着高于低 PMV 组患者。 RDI 是我们研究患者的一个独立预后因素。此外，接受辅助S-1化疗的患者被分为3组：同时具有高RDI和高PMV的患者，A组；具有高 RDI 或高 PMV（但不是两者）的人，B 组； 3 组患者的 5 年 OS 和 RFS 差异有统计学意义（5 年总生存率：P = .023，5 年无复发生存率： P = .001)。 RDI 和 PMV 组合的曲线下面积 (0.674) 大于单独 RDI 的曲线下面积 (0.645)。足够剂量的辅助S-1化疗对于提高胰腺导管腺癌切除患者的生存率很重要。 RDI 和 PMV 的组合可以比单独的 RDI 更有效地预测切除的胰腺导管腺癌患者的预后。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

This study aimed to investigate the prognostic relationship between relative dose intensity (RDI) of adjuvant S-1 chemotherapy and psoas muscle mass volume (PMV) in patients with resected pancreatic ductal adenocarcinoma. We enrolled 105 patients with histologically confirmed pancreatic ductal adenocarcinoma who had undergone pancreatectomy. Adjuvant S-1 chemotherapy was administered to 72 (68.6%) of the 105 patients and not to the remaining 33 patients. Patients who received adjuvant S-1 chemotherapy were stratified into high- and low-RDI groups by the cutoff value for RDI. Five-year overall survival (OS) and relapse-free survival (RFS) rates were significantly higher in the high- than in the low-RDI group. Similarly, both the 5-year OS and RFS rates were significantly greater among patients in the high-PMV group than among patients in the low-PMV group. The RDI was an independent prognostic factor in our study patients. Furthermore, patients who received adjuvant S-1 chemotherapy were stratified into 3 groups: those with both high RDI and high-PMV, Group A; those with either high RDI or high PMV (but not both), Group B; and those with both low RDI and low-PMV, group C. There were statistically significant differences in 5-year OS and RFS between 3 patient groups (5-year overall survival: P = .023, 5-year relapse-free survival: P = .001). The area under the curve for the combination of RDI and PMV (0.674) was greater than that for RDI alone (0.645). A sufficient dosage of adjuvant S-1 chemotherapy is important in improving survival of patients with resected pancreatic ductal adenocarcinoma. A combination of RDI and PMV may predict the prognosis of patients with resected pancreatic ductal adenocarcinoma more effective than RDI alone.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.